PIK3CG and B-cell non-Hodgkin lymphoma: Alongside the phenomena of immunological dysfunction shared by almost all drugs in this group, for duvelisib, a dual inhibitor of the delta and gamma isoforms of PIK3, the additional inhibition of the gamma isoform could inhibit T-cell and macrophage polarization, thus disrupting the tumor microenvironment believed to be important in the development and maintenance of indolent B-cell lymphomas [116].